{
    "root": "35ce99f0-8af9-4660-e063-6294a90a54bf",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Temozolomide",
    "value": "20250523",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TARTARIC ACID",
            "code": "W4888I119H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "TEMOZOLOMIDE",
            "code": "YF1K15M17Y",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_72564"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        }
    ],
    "indications": {
        "text": "temozolomide alkylating indicated treatment adults : newly diagnosed glioblastoma concomitantly radiotherapy maintenance treatment . ( 1.1 ) anaplastic astrocytoma . ( 1.2 ) adjuvant treatment adults newly diagnosed anaplastic astrocytoma . ( 1.2 ) treatment adults refractory anaplastic astrocytoma . ( 1.2 )",
        "doid_entities": [
            {
                "text": "glioblastoma (DOID:3068)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3068"
            },
            {
                "text": "anaplastic astrocytoma (DOID:3078)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3078"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "administer either orally intravenously . ( 2.4 ) newly diagnosed glioblastoma : 75 mg/m 2 daily 42 49 days concomitant focal radiotherapy followed initial maintenance dose 150 mg/m 2 daily days 1 5 28-day cycle 6 cycles . may increase maintenance dose 200 mg/m 2 cycles 2 6 based toxicity . ( 2.1 ) provide pneumocystis pneumonia ( pcp ) prophylaxis concomitant phase continue patients develop lymphopenia resolution grade 1 less . ( 2.1 ) adjuvant treatment newly diagnosed anaplastic astrocytoma : beginning 4 weeks end radiotherapy , administer temozolomide capsules orally single dose days 1-5 28-day cycle 12 cycles . recommended cycle 1 150 mg/m 2 per day cycles 2 12 200 mg/m 2 patient experienced minimal toxicity cycle 1 . ( 2.2 ) refractory anaplastic astrocytoma : initial dose 150 mg/m 2 daily days 1 5 28-day cycle . ( 2.2 )",
        "doid_entities": [
            {
                "text": "glioblastoma (DOID:3068)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3068"
            },
            {
                "text": "pneumocystis pneumonia (DOID:11339)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11339"
            },
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            },
            {
                "text": "lymphopenia (DOID:614)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_614"
            },
            {
                "text": "anaplastic astrocytoma (DOID:3078)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3078"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "temozolomide hazardous . follow applicable special handling disposal procedures . 1 temozolomide capsules , usp temozolomide capsules , usp supplied amber glass bottles child-resistant polypropylene caps child-resistant sachet packs containing following capsule strengths : temozolomide capsules 5 mg : white bodies green caps . capsule body imprinted ' 5 ' . cap imprinted 'tmz ' . supplied follows : amber glass bottles 5 count \u2013 ndc 16729-048-53 14 count \u2013 ndc 16729-048-54 sachet packs ( carton contains individual sachet one capsule ) : 5 count \u2013 ndc 16729-048-31 14 count \u2013 ndc 16729-048-04 temozolomide capsules 20 mg : white bodies yellow caps . capsule body imprinted '20 ' . cap imprinted 'tmz ' . supplied follows : amber glass bottles 5 count \u2013 ndc 16729-049-53 14 count \u2013 ndc 16729-049-54 sachet packs ( carton contains individual sachet one capsule ) : 5 count \u2013 ndc 16729-049-31 14 count \u2013 ndc 16729-049-04 temozolomide capsules 100 mg : white bodies pink caps . capsule body imprinted '100 ' . cap imprinted 'tmz ' . supplied follows : amber glass bottles 5 count \u2013 ndc 16729-050-53 14 count \u2013 ndc 16729-050-54 sachet packs ( carton contains individual sachet one capsule ) : 5 count \u2013 ndc 16729-050-31 14 count \u2013 ndc 16729-050-04 temozolomide capsules 140 mg : white bodies transparent blue caps . capsule body imprinted '140 ' . cap imprinted 'tmz ' . supplied follows : amber glass bottles 5 count \u2013 ndc 16729-129-53 14 count \u2013 ndc 16729-129-54 sachet packs ( carton contains individual sachet one capsule ) : 5 count \u2013 ndc 16729-129-31 14 count \u2013 ndc 16729-129-04 temozolomide capsules 180 mg : white bodies maroon caps . capsule body imprinted '180 ' . cap imprinted 'tmz ' . supplied follows : amber glass bottles 5 count \u2013 ndc 16729-130-53 14 count \u2013 ndc 16729-130-54 sachet packs ( carton contains individual sachet one capsule ) : 5 count \u2013 ndc 16729-130-31 14 count \u2013 ndc 16729-130-04 temozolomide capsules 250 mg : white bodies white caps . capsule body imprinted '250 ' . cap imprinted 'tmz ' . supplied follows : amber glass bottles 5 count \u2013 ndc 16729-051-53 sachet packs ( carton contains individual sachet one capsule ) : 5 count \u2013 ndc 16729-051-31 store temozolomide capsules 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) .",
    "adverseReactions": "temozolomide contraindicated patients history serious hypersensitivity : temozolomide ingredients temozolomide capsules ; dacarbazine , since temozolomide dacarbazine metabolized active metabolite 5- ( 3methyltriazen-1-yl ) -imidazole-4-carboxamide . temozolomide included anaphylaxis [ ( 6.2 ) ] .",
    "indications_original": "Temozolomide is an alkylating drug indicated for the treatment of adults with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Anaplastic astrocytoma. ( 1.2 ) Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma.( 1.2 ) Treatment of adults with refractory anaplastic astrocytoma. ( 1.2 )",
    "contraindications_original": "Administer either orally or intravenously.( 2.4 ) Newly Diagnosed Glioblastoma : 75 mg/m 2 once daily for 42 to 49 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m 2 once daily for Days 1 to 5 of each 28-day cycle for 6 cycles. May increase maintenance dose to 200 mg/m 2 for Cycles 2 to 6 based on toxicity. ( 2.1 ) Provide Pneumocystis pneumonia (PCP) prophylaxis during concomitant phase and continue in patients who develop lymphopenia until resolution to Grade 1 or less. ( 2.1 ) Adjuvant Treatment of Newly Diagnosed Anaplastic Astrocytoma: Beginning 4 weeks after the end of radiotherapy, administer temozolomide capsules orally in a single dose on days 1-5 of a 28-day cycle for 12 cycles. The recommended dosage for Cycle 1 is 150 mg/m 2 per day and for Cycles 2 to 12 is 200 mg/m 2 if patient experienced no or minimal toxicity in Cycle 1. ( 2.2 ) Refractory Anaplastic Astrocytoma : Initial dose of 150 mg/m 2 once daily on Days 1 to 5 of each 28-day cycle. ( 2.2 )",
    "warningsAndPrecautions_original": "Temozolomide is a hazardous drug. Follow applicable special handling and disposal procedures.\n \n  1\n                  \n                  \n                     Temozolomide capsules, USP\n                  \n                  Temozolomide capsules, USP are supplied in amber glass bottles with child-resistant polypropylene caps and child-resistant sachet packs containing the following capsule strengths:\n                  \n                     Temozolomide Capsules 5 mg:have white bodies with green caps. The capsule body is imprinted with '5'. The cap is imprinted with 'TMZ'. \n    They are supplied as follows: \n    Amber Glass Bottles \n    5 count \u2013 NDC 16729-048-53 \n    14 count \u2013 NDC 16729-048-54 \n    Sachet Packs (Carton Contains Individual Sachet with One Capsule each): \n    5 count \u2013 NDC 16729-048-31 \n    14 count \u2013 NDC 16729-048-04\n\n \n                  \n                     Temozolomide Capsules 20 mg:have white bodies with yellow caps. The capsule body is imprinted with '20'. The cap is imprinted with 'TMZ'. \n    They are supplied as follows: \n    Amber Glass Bottles \n    5 count \u2013 NDC 16729-049-53 \n    14 count \u2013 NDC 16729-049-54 \n    Sachet Packs (Carton Contains Individual Sachet with One Capsule each): \n    5 count \u2013 NDC 16729-049-31 \n    14 count \u2013 NDC 16729-049-04\n\n \n                  \n                     Temozolomide Capsules 100 mg:have white bodies with pink caps. The capsule body is imprinted with '100'. The cap is imprinted with 'TMZ'. \n    They are supplied as follows: \n    Amber Glass Bottles \n    5 count \u2013 NDC 16729-050-53 \n    14 count \u2013 NDC 16729-050-54 \n    Sachet Packs (Carton Contains Individual Sachet with One Capsule each): \n    5 count \u2013 NDC 16729-050-31 \n    14 count \u2013 NDC 16729-050-04\n\n \n                  \n                     Temozolomide Capsules 140 mg:have white bodies with transparent blue caps. The capsule body is imprinted with '140'. The cap is imprinted with 'TMZ'. \n    They are supplied as follows: \n    Amber Glass Bottles \n    5 count \u2013 NDC 16729-129-53 \n    14 count \u2013 NDC 16729-129-54 \n    Sachet Packs (Carton Contains Individual Sachet with One Capsule each): \n    5 count \u2013 NDC 16729-129-31 \n    14 count \u2013 NDC 16729-129-04\n\n \n                  \n                     Temozolomide Capsules 180 mg:have white bodies with maroon caps. The capsule body is imprinted with '180'. The cap is imprinted with 'TMZ'. \n    They are supplied as follows: \n    Amber Glass Bottles \n    5 count \u2013 NDC 16729-130-53 \n    14 count \u2013 NDC 16729-130-54 \n    Sachet Packs (Carton Contains Individual Sachet with One Capsule each): \n    5 count \u2013 NDC 16729-130-31 \n    14 count \u2013 NDC 16729-130-04\n\n \n                  \n                     Temozolomide Capsules 250 mg:have white bodies with white caps. The capsule body is imprinted with '250'. The cap is imprinted with 'TMZ'. \n    They are supplied as follows: \n    Amber Glass Bottles \n    5 count \u2013 NDC 16729-051-53 \n    Sachet Packs (Carton Contains Individual Sachet with One Capsule each): \n    5 count \u2013 NDC 16729-051-31\n\n \n                  Store temozolomide capsules at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F).",
    "adverseReactions_original": "Temozolomide is contraindicated in patients with a history of serious hypersensitivity reactions to:\n                  \n                  \n                     temozolomide or any other ingredients in temozolomide capsules; and\n                     dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3methyltriazen-1-yl)-imidazole-4-carboxamide.\n                  \n                  Reactions to temozolomide have included anaphylaxis\n \n  [see\n  \n   Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Temozolomide",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_72564"
        }
    ]
}